JP2024547113A5 - - Google Patents
Info
- Publication number
- JP2024547113A5 JP2024547113A5 JP2024537986A JP2024537986A JP2024547113A5 JP 2024547113 A5 JP2024547113 A5 JP 2024547113A5 JP 2024537986 A JP2024537986 A JP 2024537986A JP 2024537986 A JP2024537986 A JP 2024537986A JP 2024547113 A5 JP2024547113 A5 JP 2024547113A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- crystal
- characteristic peaks
- oxetan
- dihydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111584574 | 2021-12-23 | ||
| CN202111584574.4 | 2021-12-23 | ||
| PCT/CN2022/141418 WO2023116882A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547113A JP2024547113A (ja) | 2024-12-26 |
| JP2024547113A5 true JP2024547113A5 (enExample) | 2026-01-08 |
Family
ID=86901360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537986A Pending JP2024547113A (ja) | 2021-12-23 | 2022-12-23 | Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250049777A1 (enExample) |
| EP (2) | EP4455141B1 (enExample) |
| JP (1) | JP2024547113A (enExample) |
| KR (1) | KR20240125003A (enExample) |
| CN (1) | CN118434730A (enExample) |
| AU (1) | AU2022418658A1 (enExample) |
| CA (1) | CA3241670A1 (enExample) |
| DK (1) | DK4455141T3 (enExample) |
| MX (1) | MX2024007906A (enExample) |
| TW (1) | TW202328114A (enExample) |
| WO (1) | WO2023116882A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202535353A (zh) * | 2024-01-09 | 2025-09-16 | 大陸商山東盛迪醫藥有限公司 | 一種ｇｌｐ－１ｒ激動劑醫藥組成物及其應用 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| EP4166142A4 (en) * | 2020-06-10 | 2024-06-26 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| CN119930605A (zh) * | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022228490A1 (zh) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 EP EP22910193.6A patent/EP4455141B1/en active Active
- 2022-12-23 CN CN202280085412.2A patent/CN118434730A/zh active Pending
- 2022-12-23 EP EP26158421.3A patent/EP4732838A2/en active Pending
- 2022-12-23 US US18/721,934 patent/US20250049777A1/en active Pending
- 2022-12-23 JP JP2024537986A patent/JP2024547113A/ja active Pending
- 2022-12-23 KR KR1020247024147A patent/KR20240125003A/ko active Pending
- 2022-12-23 WO PCT/CN2022/141418 patent/WO2023116882A1/zh not_active Ceased
- 2022-12-23 MX MX2024007906A patent/MX2024007906A/es unknown
- 2022-12-23 AU AU2022418658A patent/AU2022418658A1/en active Pending
- 2022-12-23 TW TW111149827A patent/TW202328114A/zh unknown
- 2022-12-23 CA CA3241670A patent/CA3241670A1/en active Pending
- 2022-12-23 DK DK22910193.6T patent/DK4455141T3/da active